Kolon TissueGene Says Damages Claim Falls to KRW 28.44 Billion
Bitget2026/11/05 09:29- Kolon TissueGene’s Nov. 5, 2026, correction reduced the damages claim to KRW 28.44 billion from KRW 29.52 billion.
- The revised claim represents 11.25% of equity, down from 11.68%.
- Additional plaintiff withdrawals reduced the plaintiff count to 949 from 963.
- The company plans to appoint legal counsel to defend the lawsuit.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Barrick’s Marquee gold project faces hazy study timing
Japanese and South Korean stock markets open

Marvell Technology (MRVL.US) $115 billion "merger of the century" faces lukewarm reception! Stock has dropped over 40%, experts estimate only a 50% chance of completion
Marvell plans to acquire Lamington for 115 billions USD to strengthen its position in AI, but the probability of completion is only 50%. The two stocks have dropped by nearly 40% and about 35% respectively, with Chinese regulatory approval being the biggest uncertainty.